Cadila Healthcare inks pact to extend tenure of JV with Bayer

Published On 2021-05-06 07:30 GMT   |   Update On 2021-05-06 12:36 GMT
Advertisement

New Delhi: Drug firm Cadila Healthcare on Wednesday said it has inked a pact to extend the tenure of a joint venture with Bayer Pte ltd for two months to explore possibilities of further collaboration.

The company has signed an agreement to extend the tenure of the joint venture with a Bayer Group firm for a period of two months, Cadila Healthcare said in a regulatory filing.

Read also: Cadila Healthcare eyes doubling Covid-19 vaccine capacity amid record India surge: Bloomberg

Advertisement

The companies had entered into an agreement on January 28, 2011 for the joint venture, pursuant to which a company was formed to carry on with the business of marketing of pharmaceutical products, it added.

Read also: Zydus Cadila gets DCGI nod to moderate Covid-19 drug Virafin



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News